OliX Pharmaceuticals,Inc (226950.KQ)
KRW 18430.0
(-6.07%)
KRW 18430.0
(-6.07%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -18.18 Billion KRW | 18.73% |
| 2022 | -22.37 Billion KRW | 7.65% |
| 2021 | -24.22 Billion KRW | -49.18% |
| 2020 | -16.24 Billion KRW | -7.44% |
| 2019 | -15.11 Billion KRW | -81.65% |
| 2018 | -8.32 Billion KRW | -53.82% |
| 2017 | -5.41 Billion KRW | -41.56% |
| 2016 | -3.82 Billion KRW | -75.51% |
| 2015 | -2.17 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -10.09 Billion KRW | -544.62% |
| 2024 Q2 | -3.77 Billion KRW | 62.62% |
| 2023 Q1 | -7.81 Billion KRW | -158.72% |
| 2023 FY | -18.18 Billion KRW | 18.73% |
| 2023 Q3 | -5.04 Billion KRW | 33.6% |
| 2023 Q2 | -7.59 Billion KRW | 2.82% |
| 2023 Q4 | 2.27 Billion KRW | 145.01% |
| 2022 Q3 | -4.48 Billion KRW | 39.73% |
| 2022 Q1 | -7.41 Billion KRW | -14.66% |
| 2022 FY | -22.37 Billion KRW | 7.65% |
| 2022 Q4 | -3.02 Billion KRW | 32.7% |
| 2022 Q2 | -7.44 Billion KRW | -0.42% |
| 2021 Q1 | -5.2 Billion KRW | -25.18% |
| 2021 FY | -24.22 Billion KRW | -49.18% |
| 2021 Q4 | -6.46 Billion KRW | 16.76% |
| 2021 Q2 | -5.98 Billion KRW | -14.95% |
| 2021 Q3 | -7.77 Billion KRW | -29.94% |
| 2020 Q3 | -4.29 Billion KRW | 8.76% |
| 2020 Q2 | -4.71 Billion KRW | -53.1% |
| 2020 Q1 | -3.07 Billion KRW | 40.94% |
| 2020 Q4 | -4.15 Billion KRW | 3.3% |
| 2020 FY | -16.24 Billion KRW | -7.44% |
| 2019 Q2 | -3.65 Billion KRW | -40.2% |
| 2019 Q1 | -2.6 Billion KRW | -29.2% |
| 2019 Q3 | -3.63 Billion KRW | 0.59% |
| 2019 Q4 | -5.2 Billion KRW | -43.21% |
| 2019 FY | -15.11 Billion KRW | -81.65% |
| 2018 Q4 | -2.02 Billion KRW | 0.85% |
| 2018 FY | -8.32 Billion KRW | -53.82% |
| 2018 Q3 | -2.03 Billion KRW | 6.13% |
| 2018 Q2 | -2.17 Billion KRW | -8.2% |
| 2018 Q1 | -2 Billion KRW | 0.0% |
| 2017 FY | -5.41 Billion KRW | -41.56% |
| 2016 FY | -3.82 Billion KRW | -75.51% |
| 2015 FY | -2.17 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 85.455% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -453.594% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 1844.794% |
| Bioneer Corporation | 791.75 Million KRW | 2396.846% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | -258.414% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 27.637% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 41.172% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 48.404% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | -92.944% |
| Medy-Tox Inc. | 17.32 Billion KRW | 204.982% |
| Peptron, Inc. | -15.6 Billion KRW | -16.551% |
| Amicogen, Inc. | 2.05 Billion KRW | 984.44% |
| Genexine, Inc. | -41.24 Billion KRW | 55.905% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | -109.021% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 77.5% |
| ALTEOGEN Inc. | -9.73 Billion KRW | -86.768% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 118.038% |
| SillaJen, Inc. | -21.34 Billion KRW | 14.806% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 790.502% |
| Genomictree Inc. | -17.3 Billion KRW | -5.096% |
| MedPacto, Inc. | -28.75 Billion KRW | 36.751% |
| D&D Pharmatech | -13.48 Billion KRW | -34.844% |
| EASY BIO,Inc. | 20.63 Billion KRW | 188.145% |
| GI Innovation, Inc. | -55.6 Billion KRW | 67.295% |